... The two other insulin biosimilars are long-acting: insulin glargine-yfgn (Semglee) and insulin glargine-aglr (Rezvoglar), both alternatives to insulin glargine (Lantus). Biosimilars are designed to work the same way as their brand-name counterparts, with no meaningful differences in safety or effectiveness. ...
... The two other insulin biosimilars are long-acting: insulin glargine-yfgn (Semglee) and insulin glargine-aglr (Rezvoglar), both alternatives to insulin glargine (Lantus). Biosimilars are designed to work the same way as their brand-name counterparts, with no meaningful differences in safety or effectiveness. ...